MKGA.F Stock Overview
Merck KGaA operates as a science and technology company in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for MKGA.F from our risk checks.
Merck KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €158.36 |
| 52 Week High | €186.41 |
| 52 Week Low | €143.46 |
| Beta | 0.67 |
| 1 Month Change | -8.99% |
| 3 Month Change | -2.11% |
| 1 Year Change | -11.96% |
| 3 Year Change | -9.69% |
| 5 Year Change | 50.32% |
| Change since IPO | 453.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| MKGA.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.2% | 0.08% | 1.2% |
| 1Y | -12.0% | 13.2% | 24.9% |
Return vs Industry: MKGA.F underperformed the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: MKGA.F underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| MKGA.F volatility | |
|---|---|
| MKGA.F Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MKGA.F has not had significant price volatility in the past 3 months.
Volatility Over Time: MKGA.F's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1668 | 62,908 | Belen Garijo Lopez | www.emdgroup.com |
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Merck KGaA Fundamentals Summary
| MKGA.F fundamental statistics | |
|---|---|
| Market cap | US$70.89b |
| Earnings (TTM) | US$3.02b |
| Revenue (TTM) | US$22.47b |
23.5x
P/E Ratio3.2x
P/S RatioIs MKGA.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MKGA.F income statement (TTM) | |
|---|---|
| Revenue | €20.99b |
| Cost of Revenue | €8.56b |
| Gross Profit | €12.44b |
| Other Expenses | €9.61b |
| Earnings | €2.82b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | 6.50 |
| Gross Margin | 59.23% |
| Net Profit Margin | 13.45% |
| Debt/Equity Ratio | 35.2% |
How did MKGA.F perform over the long term?
See historical performance and comparison